Aaron N Hata

List of Publications by Year
in descending order

66 papers	6,938 citations	117625 34 h-index	118850 62 g-index
68 all docs	68 docs citations	68 times ranked	10108 citing authors

#	Article	IF	Citations
1	Stitchr: stitching coding TCR nucleotide sequences from V/J/CDR3 information. Nucleic Acids Research, 2022, 50, e68-e68.	14.5	8
2	Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells. Science Translational Medicine, 2022, 14, eabc7480.	12.4	14
3	Abstract 1300: Targeted therapies prime lung cancer cells for macrophage-mediated destruction. Cancer Research, 2022, 82, 1300-1300.	0.9	0
4	Abstract 2150: LKB1 loss rewires JNK-induced apoptotic protein dynamics through NUAKs and sensitizes KRAS-mutant non-small cell lung cancers to combined KRAS G12C + MCL-1 blockade. Cancer Research, 2022, 82, 2150-2150.	0.9	0
5	Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nature Cancer, 2022, 3, 710-722.	13.2	28
6	Complete evaluation of resistance mechanisms to first-line osimertinib requires tissue biopsy.. Journal of Clinical Oncology, 2022, 40, e21154-e21154.	1.6	1
7	MicroRNA-21 guide and passenger strand regulation of adenylosuccinate lyase-mediated purine metabolism promotes transition to an EGFR-TKI-tolerant persister state. Cancer Gene Therapy, 2022, 29, 1878-1894.	4.6	6
8	Targeting the DNA replication stress phenotype of KRAS mutant cancer cells. Scientific Reports, 2021, 11, 3656.	3.3	10
9	Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusionâ€“Positive Lung Cancer. Clinical Cancer Research, 2021, 27, 2899-2909.	7.0	62
10	Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RASâ€“MAPK Reactivation. Cancer Discovery, 2021, 11, 1913-1922.	9.4	243
11	A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. Journal of Thoracic Oncology, 2021, 16, 850-859.	1.1	35
12	Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer. Cancers, 2021, 13, 2666.	3.7	79
13	Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer. Nature Communications, 2021, 12, 3697.	12.8	14
14	Alginate-based 3D cancer cell culture for therapeutic response modeling. STAR Protocols, 2021, 2, 100391.	1.2	2
15	Abstract 982:LKB1loss rewires stress signaling-induced apoptotic protein dynamics and sensitizesKRAS-mutant non-small cell lung cancers to combined MAPK + MCL-1 blockade. , 2021, , .		0
16	Screening and Validation of Molecular Targeted Radiosensitizers. International Journal of Radiation Oncology Biology Physics, 2021, 111, e63-e74.	0.8	10
17	Cycling cancer persister cells arise from lineages with distinct programs. Nature, 2021, 596, 576-582.	27.8	236
18	Age-dependent regulation of SARS-CoV-2 cell entry genes and cell death programs correlates with COVID-19 severity. Science Advances, 2021, 7, .	10.3	49

#	Article	IF	Citations
19	Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. Cancer Cell, 2021, 39, 1531-1547.e10.	16.8	106
20	Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. Npj Precision Oncology, 2020, 4, 21.	5.4	36
21	Modeling Resistance and Recurrence Patterns of Combined Targetedâ€"Chemoradiotherapy Predicts Benefit of Shorter Induction Period. Cancer Research, 2020, 80, 5121-5133.	0.9	7
22	Investigating New Mechanisms of Acquired Resistance to Targeted Therapies: If You Hit Them Harder, Do They Get Up Differently?. Cancer Research, 2020, 80, 25-26.	0.9	4
23	Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights. , 2020, 210, 107522.		56
24	Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nature Biotechnology, 2020, 38, 420-425.	17.5	48
25	Can the Help Match the Hype? KRASG12C-Specific Inhibitors and Beyond. Cancer Discovery, 2020, 10, 20-22.	9.4	16
26	Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue. Clinical Cancer Research, 2020, 26, 2441-2443.	7.0	8
27	MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. Clinical Cancer Research, 2020, 26, 2535-2545.	7.0	127
28	Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities. , 2019, 193, 20-30.		49
29	The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nature Communications, 2019, 10, 3604.	12.8	99
30	Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. Cancer Discovery, 2019, 9, 1372-1387.	9.4	158
31	Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. Oncogene, 2019, 38, 6399-6413.	5.9	160
32	Sequence, Treat, Repeat: Addressing Resistance in EGFR-Mutant NSCLC. Journal of Thoracic Oncology, 2019, 14, 1875-1877.	1.1	1
33	Fatty acids and cancer-amplified ZDHHC19 promote STAT3 activation through S-palmitoylation. Nature, 2019, 573, 139-143.	27.8	45
34	Treatment with Next-Generation ALK Inhibitors Fuels Plasma <i>ALK</i> Mutation Diversity. Clinical Cancer Research, 2019, 25, 6662-6670.	7.0	122
35	Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity. Cell Reports, 2019, 27, 3422-3432.e4.	6.4	42
36	Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies. Cancer Research, 2019, 79, 3776-3788.	0.9	32

#	Article	IF	Citations
37	Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion. Journal of Thoracic Oncology, 2019, 14, e226-e228.	1.1	24
38	KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition. Clinical Cancer Research, 2019, 25, 796-807.	7.0	175
39	Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. Cancer Discovery, 2018, 8, 600-615.	9.4	157
40	SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. Nature Medicine, 2018, 24, 512-517.	30.7	155
41	Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer. Cancer Discovery, 2018, 8, 714-729.	9.4	228
42	Distinct evolutionary paths to TKI resistance in NSCLC. Cell Cycle, 2018, 17, 298-299.	2.6	4
43	Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM. Clinical Cancer Research, 2018, 24, 197-208.	7.0	74
44	Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. JCO Precision Oncology, 2018, 2018, 1-15.	3.0	17
45	Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA. JCO Precision Oncology, 2018, 2018, 1-14.	3.0	86
46	Impact of <i>EML4-ALK</i> Variant on Resistance Mechanisms and Clinical Outcomes in <i>ALK</i>-Positive Lung Cancer. Journal of Clinical Oncology, 2018, 36, 1199-1206.	1.6	246
47	Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i>-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> Fusion. Cancer Discovery, 2018, 8, 1529-1539.	9.4	342
48	Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in <i>KRAS</i>-Mutant Nonâ€“Small Cell Lung Cancer. Cancer Discovery, 2018, 8, 1598-1613.	9.4	71
49	Increased Synthesis of MCL-1 Protein Underlies Initial Survival of <i>EGFR</i>-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target. Clinical Cancer Research, 2018, 24, 5658-5672.	7.0	38
50	Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC).. Journal of Clinical Oncology, 2018, 36, 8571-8571.	1.6	4
51	Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC.. Journal of Clinical Oncology, 2018, 36, e21231-e21231.	1.6	6
52	Programmed Cell Death Ligand (PD-L1) Expression inÂStage II and III Lung Adenocarcinomas and NodalÂMetastases. Journal of Thoracic Oncology, 2017, 12, 458-466.	1.1	120
53	Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancerâ€“Transformed <i>EGFR</i> Mutant Nonâ€“Small-Cell Lung Cancer. JCO Precision Oncology, 2017, 1, 1-7.	3.0	8
54	Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i>-Positive Nonâ€“Small-Cell Lung Cancer. JCO Precision Oncology, 2017, 2017, 1-13.	3.0	158

#	Article	IF	Citations
55	MET amplification (amp) as a resistance mechanism to osimertinib.. Journal of Clinical Oncology, 2017, 35, 9020-9020.	1.6	45
56	<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Nonâ€"Small Cell Lung Cancer: A Retrospective Analysis. Clinical Cancer Research, 2016, 22, 4585-4593.	7.0	977
57	Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment. Journal of Thoracic Oncology, 2016, 11, 1869-1878.	1.1	81
58	Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nature Medicine, 2016, 22, 262-269.	30.7	768
59	Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination. Cancer Cell, 2016, 29, 159-172.	16.8	104
60	Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1288-96.	7.1	110
61	Heterogeneity Underlies the Emergence of <i>EGFR</i>T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discovery, 2015, 5, 713-722.	9.4	429
62	The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics. Cancer Discovery, 2015, 5, 475-487.	9.4	501
63	Clinicopathological characteristics of squamous cell carcinoma of the lung with programmed cell death ligand 1 (PD-L1) protein expression.. Journal of Clinical Oncology, 2015, 33, 7554-7554.	1.6	4
64	Clinicopathological and molecular parameters of lung adenocarcinomas (ADC) associated with programmed cell death ligand 1 (PD-L1) protein expression.. Journal of Clinical Oncology, 2015, 33, 7555-7555.	1.6	3
65	Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 8012-8012.	1.6	16
66	Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers. Cancer Research, 2014, 74, 3146-3156.	0.9	69